5-methyl-1-hexyn-3-one | 18927-47-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-methyl-1-hexyn-3-one
• 英文别名: 5-methylhex-1-yn-3-one
• CAS: 18927-47-4
• 化学式: C₇H₁₀O
• 分子量: 110.156
• InChiKey: BWHPZOCATNXQGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-methyl-1-hexyn-3-one 、 3-氨基-2-环己烯-1-酮 以65%的产率得到
  参考文献：
  名称：

  SCHROEDER E.; LEHMANN M.; BOETTCHER I., EUR. J. MED. CHEM.-CHIM. THER., 1979, 14, NO 4, 309-315

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基-1-己炔-3-醇 在 chromium(VI) oxide 、 硫酸 作用下， 生成 5-methyl-1-hexyn-3-one
  参考文献：
  名称：

  Mechanisms of nucleophilic additions to mono-substituted diacetylenes

  摘要：

  DOI：

  10.1007/bf00913314

文献信息

• 3,5-(Un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H- pyrrolo[2,3-b]pyrazine dual ITK and JAK3 Kinase Inhibitors
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20140315909A1

  公开（公告）日：2014-10-23

  The present invention relates to compounds described by Formula I: salts thereof, their synthesis, and their use as ITK and JAK3 inhibitors including such compounds and methods of using said compounds in the treatment of various diseases and or disorders such disease associated with abnormal cell growth such as autoimmune, inflammation, rheumatoid arthritis, systemic lupus erythematosus, atherosclerosis, ulcerative colitis, psoriatic arthritis, psoriasis, Crohn's, metabolic and cancer diseases. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions and processes for preparing the compounds of the invention.

  本发明涉及由式I描述的化合物： 其盐，它们的合成，以及它们作为ITK和JAK3抑制剂的用途，包括这些化合物以及使用这些化合物治疗各种疾病和/或疾病的方法，这些疾病与异常细胞生长有关，如自身免疫、炎症、类风湿关节炎、系统性红斑狼疮、动脉粥样硬化、溃疡性结肠炎、银屑病性关节炎、银屑病、克罗恩病、代谢和癌症疾病。本发明还提供包括本发明化合物的药学上可接受的组合物以及使用这些组合物的方法和制备本发明化合物的方法。
• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。
• Mutation of Cysteine-295 to Alanine in Secondary Alcohol Dehydrogenase from Thermoanaerobacter ethanolicus Affects the Enantioselectivity and Substrate Specificity of Ketone Reductions
  作者：Christian Heiss、Maris Laivenieks、J.Gregory Zeikus、Robert S Phillips

  DOI：10.1016/s0968-0896(01)00073-6

  日期：2001.7

  The mutation of Cys-295 to alanine in Thermoanaerobacter ethanolicus secondary alcohol dehydrogenase (SADH) was performed to give C295A SADH, on the basis of molecular modeling studies utilizing the X-ray crystal structure coordinates of the highly homologous T. brockii secondary alcohol dehydrogenase (1YKF.PDB). This mutant SADH has activity for 2-propanol comparable to wild-type SADH. However, the

  在利用高度同源的布氏螺旋体仲醇脱氢酶（X射线晶体结构坐标）进行的分子建模研究的基础上，进行了乙醇热厌氧乙醇仲醇脱氢酶（SADH）中Cys-295突变为丙氨酸，得到C295A SADH。 1YKF.PDB）。该突变体SADH具有与野生型SADH相当的2-丙醇活性。然而，发现在一些乙炔基酮还原为相应的手性炔丙醇中，C295A突变引起对映选择性向（S）-构型的明显转变。该结果证实了我们的预测，即Cys-295是小的烷基结合袋的一部分，其大小决定了酮底物的结合方向，因此决定了产物醇的立体化学构型。此外，与野生型SADH相比，C295A SADH对叔丁基和某些α支化酮的活性高得多。C295A突变不影响SADH的硫酯还原酶活性。C295A SADH具有更广泛的底物特异性和改变的立体选择性，使其成为非对称还原的潜在有用工具。
• STEPWISE ASSEMBLED CAPTURE COMPOUNDS COMPRISING A CLEAVABLE FUNCTION AND METHOD FOR ISOLATING AND/OR CHARACTERIZING BIOMOLECULES OR BIOMOLECULE FRAGMENTS, IN PARTICULAR PROTEINS OR PROTEIN FRAGMENTS, OF COMPLEX MIXTURES
  申请人：CAPROTEC BIOANALYTICS GMBH

  公开号：US20160349268A1

  公开（公告）日：2016-12-01

  The invention relates to a process for isolating and/or characterising biomolecules and/or biomolecule fragments, in particular proteins and/or protein fragments, comprising the steps: provision of an immobilized compound IC through the interaction of a capture compound CC and the target compound T and a carrier compound CCB, carrying out a division step, in which a cleavable function F is cleaved, and a division compound DC is produced, and isolation and/or characterisation of said division compound DC. The invention relates further to a carrier compound CCB, a capture compound CC, a precursor compound PC and a division compound DC.

  该发明涉及一种用于分离和/或表征生物分子和/或生物分子片段的过程，特别是蛋白质和/或蛋白质片段，包括以下步骤：通过捕获化合物CC与目标化合物T以及携带化合物CCB相互作用提供固定化合物IC，进行分割步骤，在该步骤中，可切割功能F被切割，产生分割化合物DC，并分离和/或表征该分割化合物DC。该发明还涉及携带化合物CCB、捕获化合物CC、前体化合物PC和分割化合物DC。
• ERK INHIBITORS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20140228322A1

  公开（公告）日：2014-08-14

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。